(CHARLESTON, SC) Oct. 19, 2017 /PRNewswire/ — Site selection for clinical trials is one of the biggest headaches for pharmaceutical Sponsors and CROs, with almost half of sites enrolling zero or one patient. Those under-performing sites annually cost Sponsors over $4 billion globally excluding opportunity costs.

Today, Devana Solutions® announced the release of MATCH PERFORMANCE, a powerful new cloud-based system to provide Sponsors and CROs with unique transparency into the timing and performance metrics of investigative sites.

“The challenge of sorting good and bad sites is difficult in a fragmented, cottage industry with very little publicly available data on research site capabilities. It is not surprising that almost half those sites enroll zero or just one patient. With industry estimates for site initiation costs at around $40,000 per site, this lack of transparency into site performance metrics is a costly problem,” explains Barry Lake, CEO of Devana Solutions®.

“Now, in the same disruptive way Uber made hailing a cab obsolete, with IGNITE FOR SITES and MATCH PERFORMANCE technology, the Sponsor or CRO gains real transparency into actual site metrics to improve trial feasibility and performance, align with top clinical research sites, reduce the cycle time and costs of a trial and, eventually, reduce the high cost of drug development.”

Sponsors and CROs currently collect data on trial site performance, but their ability to gather reliable site timing and performance metrics is mostly limited to data gathered from sites they hire for their own clinical trials. Those metrics are outdated the moment after they are gathered.

In addition, despite technological advances, it is still common practice for Sponsors and CROs to rely on self-prepared, paper feasibility submissions from sites that are often inaccurate in terms of capabilities and trial experience. These inefficiencies often force Sponsors and CROs to make assumptions on site qualifications that are not based on reliable, tangible past and current performance metrics.

The MATCH PERFORMANCE cloud technology platform addresses these problems, allowing Sponsors and CROs to align with the best research sites for each trial opportunity, by capturing and aggregating the historical and real-time performance metrics across every trial a site has completed or is running with competing Sponsor and CRO information fully blinded or de-identified.

How MATCH PERFORMANCE works

The key to MATCH PERFORMANCE’s effectiveness is in Devana Solutions’® previously launched companion technology, the recently re-branded IGNITE FOR SITES, a real-time data capture, integration and analytics platform introduced in May 2016 and used by the leading investigative sites themselves to save time and win more of the right trial awards.

IGNITE’s proprietary algorithms automatically capture, aggregate and display the timing and performance metrics of the sites on the platform. Over 150 investigative sites are using IGNITE FOR SITES to automate study pipeline, aggregate historical trial performance and track critical study information and documents with a focus on study start-up activities.

MATCH PERFORMANCE regularly synchronizes site metrics data populating from IGNITE to a secure platform used by subscribing Sponsors and CROs.  These metrics are captured instantaneously on MATCH PERFORMANCE and can be displayed and analyzed through more than 100 customized reports and easy-to-read dashboards giving instant access to important site performance measures across therapeutic indications including analysis of completed and active patient volume, contract met percentage, speed of enrollment and start-up times.

“MATCH PERFORMANCE and IGNITE FOR SITES are the leading platforms to collect, aggregate and analyze data directly from the source, clinical research sites,” added Lake.

The pricing model

At this early stage, the initial price for entry for Sponsors or CROs interested in MATCH PERFORMANCE is a commitment to purchase IGNITE FOR SITES multi-year subscriptions on behalf of a significant number of trial sites in their network.

IGNITE FOR SITES subscription model pricing starts at $450 per month for a single investigative site with two users. Multi-site and Site Network versions with five or more users can achieve per-user volume discounts based on level of customization required and access to enhanced product training and support.

FOR FURTHER INFORMATION, PLEASE CONTACT:
Emily Wike

ewike@devanasolutions.com

(CHARLESTON, SC) April 7, 2017 /PRNewswire/ — PMG Research, Inc. and Devana Solutions, LLC, today announced a long-term subscription agreement for the use of Devana’s advanced cloud-based technology across PMG’s industry-leading network of over 50 investigative site locations.

The agreement allows PMG’s integrated network of sites to adopt Devana’s Ignite for Sites platform to fully automate its operations from study lead through trial completion.

In addition to PMG’s more than 7,700 completed clinical trials, the advanced Devana Solutions® technology simultaneously tracks, aggregates and allows PMG to display and report its timing and performance metrics in real-time for all trials currently running across its entire site network.

This technology advantage, coupled with best-in-class trial management capabilities, will allow PMG Research to expand its industry leading position and secure additional trials in partnership with pharmaceutical sponsors and CROs.

Amanda Wright, Senior Director of Client Services and Communications at PMG, commented: “PMG Research has always embraced technology innovation as an important way to grow our business and to fulfill the organization’s mission of bringing clinical research to as many people as possible.

“Devana Solutions® system allows for the end-to-end capture of data that will us to continue to demonstrate to CROs and Sponsors that our performance is among the best in the industry and that PMG is committed to the highest standards.”

Barry Lake, CEO & Executive Chairman of Devana, added: “PMG is clearly a leader in the site operations enterprise and we are thrilled to partner with them.

“From the first conversation, they shared Devana Solutions’ opinion that more and better data about site performance will mean that the most capable networks of sites, like PMG Research, will win more awards, leading to shorter cycle times for trials, lower costs and, ultimately, lower cost treatments for patients.”

FOR FURTHER INFORMATION, PLEASE CONTACT:

For Devana Solutions, LLC:

Emily Wike

ewike@devanasolutions.com

For PMG Research, Inc:

Kristin Kinlaw

kkinlaw@pmg-research.com

Tel: 336-608-3506

ABOUT PMG RESEARCH (www.pmg-research.com)

PMG Research, Inc. is an integrated network of clinical research facilities with fourteen hub sites located in Champaign, IL; Ames, IA; Cary, Charlotte, Hickory, Raleigh, Rocky Mount, Salisbury, Statesville, Wilmington, and Winston-Salem, NC; Charleston, SC; and Bristol and Knoxville, TN. PMG has conducted over 7,700 research studies for hundreds of pharmaceutical sponsors and CROs since 1979. We have extensive experience conducting all phases of trials across a comprehensive list of conditions. Our mission is to bring clinical research to as many lives as possible while delivering unparalleled service and exceptional value to our clinical trial partners and stakeholders.

ABOUT DEVANA SOLUTIONS 

Devana Solutions®, LLC is a SaaS provider driven by a core belief that data transparency through technology is critical to selection of the top performing research sites to align with pharmaceutical Sponsors and CROs to reduce drug development costs and cure disease. Devana Solutions® offers two platforms, IGNITE FOR SITES and MATCH PERFORMANCE, to provide historical and real-time data capture, aggregation and display to drug development stakeholders. To learn more visit https://devanasolutions.com.